# Ona Therapeutics, SL

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ona-therapeutics-sl

- Industry: Biotechnology
- Headquarters: Barcelona, Spain
- Website: www.ona-therapeutics.com
- Total disclosed funding: $120M
- Latest round: Series B (Jun 4, 2026)
- Investors on record: 11

## About

Ona Therapeutics is a biotechnology company focused on developing innovative antibody drug conjugates for advanced cancer treatments, particularly for patients with limited therapeutic options. Founded in 2019, Ona Therapeutics, SL is based in Barcelona, Spain, and specializes in developing therapeutics for oncology. The founders, Salvador Benitah and Valerie Vanhooren (CEO), have significant experience in the industry and lead the company's strategic initiatives. In June 2026, Ona Therapeutics, SL raised EUR 74.2 million in Series B funding co-led by Columbus Venture Partners and Merieux Equity Partners, with participation from Cofides and Korys. AltamarCAM Partners, Asabys Partners, Bpifrance Investissement, Center for Technological & Industrial Development, Fund+, and Ysios Capital Partners also participated in the round. Ona Therapeutics specializes in the development of first-in-class antibody drug conjugates (ADCs) aimed at addressing the unmet medical needs of patients with advanced cancers, particularly those who have become refractory to existing treatments. The company’s pipeline includes innovative therapies, such as an undisclosed ADC targeting refractory breast cancer patients and another ADC for prevalent solid tumors. Additionally, Ona is developing a monoclonal antibody that targets CD36, a key metabolic regulator implicated in cancer progression. Their therapeutic solutions cater primarily to oncology practices and clinical institutions, focusing on North America and Europe. Ona Therapeutics generates revenue primarily through strategic partnerships and collaborations with academic institutions and clinical research organizations. These partnerships involve co-development agreements, where partners contribute funding for clinical trials in exchange for future royalties or profit-sharing from successful product launches. Revenue is also supplemented by grants and public funding that supports ongoing research and development efforts while maintaining robust operations. Specific pricing structures for products are determined during the commercialization phase.

## Funding rounds

- Series B, Jun 4, 2026, $86M — AltamarCAM Partners, Ysios Capital Partners, Korys, Cofides, Merieux Equity Partners, Bpifrance Investissement, Center for Technological & Industrial Development, Fund+, Columbus Venture Partners, Asabys Partners
- Series A, Jun 16, 2020, $34M — Ysios Capital Partners, Bpifrance Investissement, Fund+, Asabys Partners, Alta Life Sciences

## Investors

- Ysios Capital Partners (https://capitalatlas.ai/funds/ysios-capital-partners) — Series A, Series B
- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Series A, Series B
- Fund+ (https://capitalatlas.ai/funds/fund) — Series A, Series B
- Asabys Partners (https://capitalatlas.ai/funds/asabys-partners) — Series A, Series B
- Alta Life Sciences — Series A
- AltamarCAM Partners (https://capitalatlas.ai/funds/altamarcam-partners) — Series B
- Korys (https://capitalatlas.ai/funds/korys) — Series B
- Cofides (https://capitalatlas.ai/funds/cofides) — Series B
- Merieux Equity Partners (https://capitalatlas.ai/funds/merieux-equity-partners) — Series B
- Center for Technological & Industrial Development (https://capitalatlas.ai/funds/center-for-technological-industrial-development) — Series B
- Columbus Venture Partners (https://capitalatlas.ai/funds/columbus-venture-partners) — Series B